| # | % | |||||
|---|---|---|---|---|---|---|
| 1 | TREVENA INC | 2,669,280 | 28,027,000 | 22.02% | ||
| 2 | T2 BIOSYSTEMS INC | 2,018,450 | 22,082,000 | 17.35% | ||
| 3 | Life Technologies Corp | 1,827,992 | 17,969,000 | 14.12% | ||
| 4 | PULMATRIX INC | 3,607,996 | 15,154,000 | 11.90% | ||
| 5 | OCULAR THERAPEUTIX INC | 1,230,009 | 11,525,000 | 9.05% | ||
| 6 | GENOCEA BIOSCIENCES INC | 1,968,606 | 10,375,000 | 8.15% | ||
| 7 | CERULEAN PHARMA INC | 3,287,529 | 9,205,000 | 7.23% | ||
| 8 | FATE THERAPEUTICS INC COM | 2,473,186 | 8,335,000 | 6.55% | ||
| 9 | BIND THERAPEUTICS INC | 2,018,253 | 4,622,000 | 3.63% |
Portfolio data is normalized using SEC Form 13F filings, including the Original 13F-HR (0000950123-16-015144, filed 2016.02.16).
From 2023-01-03 onward, the SEC requires values to be reported in nearest dollars. Earlier filings reported values in thousands; therefore, positions shown as $0 in older filings may represent actual values between $0–$999.
